Area Drugs and Therapeutics Committee Meeting Minutes Wednesday 18th September 2024 10-12pm Microsoft Teams Meeting		
Present:	Mehrdad Malekian (Chair) Victoria Gemmell (Minutes) Lorna Templeton (item 7) Jacqueline MacDonald (item 8b) Stephanie Dundas Gail Richardson Kirsty MacFarlane	Penny Brankin Tyra Smyth Kirsty Macfarlane Graeme Bryson Craig Thurtell Rachael Kelly **Additional Attendees** Fiona Sanderson - Lead Pharmacist - Primary Care, Pharmacy Liz Savage - Lead Pharmacist Advanced Clinical Services, Pharmacy
1. Apologies:	Christine Carswell Colin Angus	Alistair Brown
2. Declaration of Interest	**Nil declared**	

Item	Notes	Action
3.	**<u>Minutes/Actions from the last meeting</u>** These were agreed as a true reflection of the meeting and can be published.	
4. **a)** **b)** **c)** **d)** **e)**	**<u>Matters Arising</u>** **Asthma Biologics – update awaited Andrew Smith** GB providing support. Planned submission for next meeting **Bimekizumab protocol – update awaited Sanjiv Nandwani** **Heart failure - Update awaited MM** MM discussed previous comments with author. The guideline is approved. MM to feedback to author. **Paediatric PCA / Postop Pain Guideline – update awaited Sharon Anderson** **Use of Tirzepatide for Treatment of Diabetes in NHSL approvals - June Currie** Amendments made as previously requested. The committee asked that the wording around indication and the SMC restriction referring to monotherapy needs further clarity. It may be better to remove the reference to use as monotherapy altogether.	

	Plans for a treatment pathway on hold due to current supply issues across various products. It was agreed this was reasonable and was accepted by the committee. Documents approved pending these changes. Please send final amended version to the ADTC mailbox for our records. The Joint Formulary will be updated to reflect these updates. **f) Management of Periop Adult Diabetic guideline – Claire Carson** Discussion about management of patients with raised HbA1c and clarity about referral process and who would ultimately be responsible. Need clarity about role of primary and secondary care. Review at 6 weeks suggested to decide if patient could go ahead with surgery but this timeframe would not be adequate in fair number of patients to achieve significant lowering of HbA1c. Agreed to ask lead author for further clarification. **g) Maternity Varicella in Pregnancy Guideline - Kelly Ann Meldrum** The Committee feels the flowchart is still not explicit enough with regard to responsibilities. It is requested that it needs to be unambiguous that patients will be managed entirely by maternity services at all points in the process. This was noted from the start of the process, including history taking, blood test requests, prescribing and supply of medication. It was also agreed that Infectious Disease teams should also be consulted for their comments	
5.	**SMC Advice-CONFIDENTIAL** Please see attached Advice from the Scottish Medicines Consortium which will be published on the SMC website **after 10.00 am** on **Monday 07 October 2024.** **FULL SUBMISSIONS** • rezafungin acetate (Rezzayo) Napp Pharmaceuticals Limited SMC2659 **ACCEPTED RESTRICTED with PAS. Refer to ID/Antimicrobials**. • selinexor (Nexpovio) Menarini Stemline UK Ltd SMC2673 **ACCEPTED with PAS. Await WoSCAN advice** • selinexor (Nexpovio) Menarini Stemline UK Ltd SMC2674 **ACCEPTED RESTRICTED with PAS. Await WoSCAN advice.** • pembrolizumab concentrate for solution for infusion (Keytruda) Merck Sharp & Dohme UK Limited SMC2689 **ACCEPTED RESTRICTED with PAS. Await WoSCAN advice** • relugolix film-coated tablets (Orgovyx) Accord-UK Ltd SMC2678 **ACCEPTED. Await WoSCAN advice** **ABBREVIATED SUBMISSION** • faricimab (Vabysmo) Roche SMC2685 **ACCEPTED with PAS. Refer to Ophthalmology for advice.** **NON SUBMISSIONS** • cemiplimab concentrate for solution for infusion (Libtayo®) Regeneron UK Limited SMC2724. **For noting.**	

	• drospirenone film-coated tablets (Slynd) Exeltis UK Limited SMC2725. **For noting.** • nivolumab concentrate for solution for infusion (Opdivo) Bristol-Myers Squibb Pharmaceuticals Limited SMC2726. **For noting.** **AMENDED ADVICE** elranatamab solution for injection (Elrexfio®) Pfizer Limited SMC2669 Minor amendments have been made to the Detailed Advice Document (DAD) for elranatamab solution for injection (Elrexfio®), as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. The DAD will be reissued to Boards on Friday 06 September 2024 and published on the website on Monday 09 September 2024. **Paediatric Licence Extensions** These were noted	
6.	**SMC follow up** RK outlined designation updates to medicines following August 24 meeting, including Avacopan and Empagliflozin. RK presented the designation update for Oxbryta (voxelotor) following correspondence with specialists, informing that potential candidates for this medicine would be considered at a national MDT.	RK
7.	**Lanarkshire Formulary** Docusate-LT gave an overview of the background to her request. This item was requested to treat clozapine-induced constipation. It was agreed this would be added to NHSL Joint Formulary for this indication. RK gave an overview of other planned changes. These were accepted. This included the proposed formulary amendment to include a section on Continuous Glucose Monitoring as part of a Hybrid Closed Loop System. It was suggested to include HEPMA team with information relating to valproate updates.	RK
8. **(a)** **(b)**	**Clinical Protocols** **Continuous Glucose Monitoring Guidance - Liz McIntyre** This is an update to previous recently authorised guidance. The update includes a change in use for Libre 2 Plus to include hybrid closed loop systems. This was approved. The corresponding formulary update was also approved**.** **Nicotine replacement to follow – Jacqueline MacDonald** JM presented a protocol which is necessary due to changes in MHRA requirements around supply of NRT products. Previous supply was via PGD, however these are no longer required. Age range for supply was confirmed and clarity was requested around dual therapy for patients under 18. Request to confirm clozapine letter with MH. Staff training has taken place, and will be ongoing.	

	The document can be returned to ADTC for final approval by email due to time pressure.	
9.	**ADTC New Medicines Decisions** These were approved and can be published.	
10. **(a)**	**Unlicensed Medicines** KM gave an update on the ongoing review of ULM policy. This is progressing.	
11.	**Medication and Clinical risk in Lanarkshire** https://www.gov.uk/drug-safety-update Nil	
12.	**Regional Cancer Advisory Network** Nil	
13.	**Patient Safety Alerts** Nil	
14.	**Lay member related items** nil	
15.	**Correspondence** Nil	
16.	**Pharmacy & NMAHP Prescribing Governance** Nil	
17.	**AOCB** Nil	
18.	**Date of next meeting** Wednesday 16th October 2024 10-12pm MS TEAMS	